Primer: Toll-like receptor signaling pathways-what do rheumatologists need to know?

Nature Clinical Practice Rheumatology

Volumn 4, Issue 6, 2008, Pages 319-327

  O'Neill, Luke A J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ALPHA INTERFERON; BACTERIUM LIPOPOLYSACCHARIDE; CD36 ANTIGEN; CHAPERONIN; CPG OLIGODEOXYNUCLEOTIDE; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; IRS 954; MAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN MD 2; SUPPRESSOR OF CYTOKINE SIGNALING 1; TIR DOMAIN CONTAINING ADAPTOR INDUCING INTERFERON; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRIF RELATED ADAPTOR MOLECULE; TUMOR NECROSIS FACTOR; TYROSINE KINASE RECEPTOR; UNC93B PROTEIN;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DIMERIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EVIDENCE BASED MEDICINE; GENE DELETION; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIGNAL TRANSDUCTION; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; INFLAMMATION; NF-KAPPA B; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 44849116504     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0802     Document Type: Review

References (51)

1. O'Neill LA (2005) Immunity's early warning system. Sci Am 292 24-31
2. Sacre SM et al. (2007) Could Toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann Rheum Dis 66 (Suppl 3) 81-86
3. Müller-Ladner U et al. (2005) Mechanisms of disease: The molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 1: 102-110
4. Lenert PS et al. (2006) Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 8: 203
5. Barrat FJ et al. (2005) Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 202: 1131-1139
6. Sheedy F and O'Neill LA (2007) The Troll in Toll: Mal and TRAM as bridges for TLR2 and TLR4 signaling. J Leukoc Biol 82: 196-203
7. O'Neill LA and Bowie AG (2007) The family of five: TIR-domain-containing adaptors in TLR signalling. Nat Rev Immunol 7: 353-364
8. Kanzler H et al. (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13 552-559
9. Schaefer L et al. (2005) The matrix component biglycan is proinflammatory and signals via Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223-2233
10. Termeer C et al. (2002) Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor-4. J Exp Med 195: 99-111
11. Roelofs MF et al. (2006) Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 176: 7021-7027
12. Park JS et al. (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-C924
13. Johnson GB et al. (2002) Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 168: 5233-5239
14. Okamura Y et al. (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276: 10229-10233
15. Smiley ST et al. (2001) Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol 167: 2887-2894
16. Brentano F et al. (2005) RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 52: 2656-2665
17. Vollmer J et al. (2005) Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 202: 1575-1585
18. Leadbetter EA et al. (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603-607
19. Pierer M et al. (2004) Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 172: 1256-1265
20. Jin MS et al. (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130: 1071-1082
21. Núñez Miguel R et al. (2007) A dimer of Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLoS ONE 2: E788
22. Ohto U et al. (2007) Crystal structure of human MD2 and its complex with antiendotoxic lipid IVa. Science 316: 1632-1634
23. Hoebe K et al. (2005) CD36 is a sensor of diacylglycerides. Nature 433: 523-527
24. Barral DC and Brenner MB (2007) CD1 antigen presentation: How it works. Nat Rev Immunol 7: 929-941
25. Mansell A et al. (2006) Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 7: 148-155
26. Gray P et al. (2006) MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem 281: 10489-10495
27. Miggin S et al. (2007) NF-κB activation by the Toll-IL-1 receptor domain-containing protein Mal is regulated by caspase-1. Proc Natl Acad Sci USA 104: 3372-3377
28. Kagan JC and Medzhitov R (2006) Phosphoinositide-mediated adapter recruitment controls Toll-like receptor signaling. Cell 125: 943-955
29. Mansell A et al. (2004) Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-κB activation by TLR2 and TLR4. J Biol Chem 279: 37227-37230
30. Khor CC et al. (2007) A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39: 523-528
31. Rowe D et al. (2006) The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc Natl Acad Sci USA 103: 6299-6304
32. McGettrick A et al. (2006) Trif-related adapter molecule is phosphorylated by protein kinase C epsilon during Toll-like receptor 4 signaling. Proc Natl Acad Sci USA 103: 9196-9201
33. Tabeta K et al. (2006) The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 7: 156-164
34. Brinkmann MM et al. (2007) The interaction between the ER membrane protein UNC93B and TLR3, 7 and 9 is crucial for TLR signaling. J Cell Biol 177: 265-275
35. de Bouteiller O et al. (2005) Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerisation and acidic pH. J Biol Chem 280: 38133-38145
36. Kyburz D et al. (2006) Mode of action of hydroxychloroquine in RA - evidence of an inhibitory effect on Toll-like receptor signaling. Nat Clin Pract Rheumatol 2: 458-459
37. Abdollahi-Roodsaz S et al. (2008) Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 118: 1-13
38. Abdollahi-Roodsaz S et al. (2007) Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 56: 2957-2967
39. Hegen M et al. (2007) Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis [doi:10.1136/ard.2007.076430]
40. Popa C et al. (2007) Bartonella quintana lipopolysaccharide is a natural antagonist of Toll-like receptor 4. Infect Immun 75: 4831-4837
41. Sacre SM et al. (2007) The Toll-like receptor adapter proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 170: 518-525
42. Barrat FJ et al. (2007) Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 37: 3582-3586
43. Ogawa S et al. (2005) Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell 122: 707-721
44. Vanags D et al. (2006) Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: A double-blind randomised trial. Lancet 368: 855-863
45. Toshchakov V et al. (2005) Differential involvement of BB loops of Toll-IL-1 resistance (TIR) domain-containing adapter proteins in TLR4-versus TLR2-mediated signal transduction. J Immunol 175 494-500
46. Bartfai T et al. (2003) A low molecular weight mimic of the Toll/ IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc Natl Acad Sci USA 100: 7971-7976
47. Low W et al. (2007) Functional cell permeable motifs within medically relevant peptides. J Biotech 129: 555-564
48. Davis CN et al. (2006) MyD88-dependent and -independent signaling by IL-1 in neurons by bifunctional Toll/IL-1 receptor domain/BB loop mimetics. Proc Natl Acad Sci USA 103: 2953-2958
49. Carty M et al. (2006) The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 7: 1074-1081
50. Marshak-Rothstein A (2006) Toll-like receptors in systemic lupus erythematosus. Nat Rev Immunol 6: 823-835
51. Rothlin CV et al. (2007) TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131: 1124-1136